Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101

Drugs in R and D

Volumn 10, Issue 1, 2010, Pages 37-45

[No Author Info available]

Author keywords

Clostridium infections; Fidaxomicin; Methicillin resistant Staphylococcus aureus infections; prevention; Research and development; therapeutic use; treatment; Vancomycin resistant enterococcal infections

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PLACEBO; RIFAXIMIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CHILL; CLOSTRIDIUM DIFFICILE INFECTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; EDEMA; ENTEROCOCCAL INFECTION; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; INFECTION PREVENTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CLOSTRIDIUM INFECTIONS; DNA-DIRECTED RNA POLYMERASES; DRUGS, INVESTIGATIONAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79953166785     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11537730-000000000-00000     Document Type: Article

References (37)

1. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Regains North American Rights to Difimicin (Par-101/Opt-80). www.optimerpharma.com, 27 Feb. 2007 Media Release
2. Par Pharmaceutical Companies Inc. Par Pharmaceutical Returns PAR-101 Marketing Rights to Optimer Pharmaceuticals. www.parpharm.com, 27 Feb. 2007 Media Release
3. Optimer Pharmaceuticals. Optimer's Lead Antibiotic CandidateMoves Into Phase 2B/3 Clinical Trials for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD). www.optimerpharma.com, 07 Feb. 2006 Media Release
4. Par Pharmaceutical Companies Inc. Par Pharmaceutical Announces Equity Investment in Optimer Pharmaceuticals. www.parpharm.com, 03 May 2005 Media Release
5. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals to Accelerate European Filing of Fidaxomicin (OPT-80). www.optimerpharma.com, 03 Mar. 2009 Media Release
6. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection. www.optimerpharma.com, 04 Feb. 2010 Media Release
7. Optimer Pharmaceuticals Inc. Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting. www.optimerpharma.com, 31 Oct. 2009 Media Release
8. Optimer Pharmaceuticals Inc. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI). www.optimerpharma.com, 15 Sep. 2009 MediaRelease
9. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection. www.optimer pharma.com, 17 May 2009 Media Release
10. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80. www.optimerpharma.com, 11 Nov. 2008 Media Release
11. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection. www.opti merpharma.com, 24 Jul. 2008 Media Release
12. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection. www.optimerpharma.com, 13 Nov. 2009 Media Release
13. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Initiates Second Phase 3 Trial of OPT 80 for CDAD. www.optimerpharma.com, 01 May 2007 Media Release
14. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial. www.opti merpharma.com, 14 Mar. 2007 Media Release
15. Optimer Pharmaceuticals Inc. Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress. www.optimerpharma. com, 27 Jun. 2008 Media Release
16. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Awarded Grant from the National Institutes of Health for Development of OPT-80 to Treat Deadly Hospital Associated Infection. www.optimerpharma.com, 08 Jan 2008 Media Release
17. Optimer Pharmaceuticals Inc. www.optimerpharma.com, 17 Oct. 2005 Media Release
18. Optimer Pharmaceuticals Inc. www.optimerpharma.com, 14 Dec. 2005 Media Release
19. Par Pharmaceutical Companies Inc. New Antibiotic Candidate Shows Promise in Treating Clostridium Difficile-Associated Diarrhea (CDAD). www.parpharm.com, 19 Dec. 2005 Media Release
20. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin. www.optimerpharma.com, 13 Apr. 2009 Media Release
21. Optimer Pharmaceuticals Inc. www.optimerpharma.com, 28 May 2008 Media Release
22. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Receives Notice of Allowance for OPT-80 Patent Application. www.optimerpharma.com, 09 Apr. 2008 tMedia Release
23. Sears P, Louie T, Mullane K, et al. Pharmacokinetics/pharmacodynamics of fidaxomicin in treatment of Clostridium difficile infection. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy: abstr. A1-1949, 12 Sep. 2009. Available from URL: http://www.icaac.org. USA [English]
24. Shangle S, Lee C, Okumu F, et al. Safety and pharmacokinetics of OPT-80 in human volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1 (plus poster) abstr. A-5, 30 Oct. 2004. USA [English]. Clinical Trials Insight
25. Louie T, Miller M, Donskey C, et al. Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: Final Program: 226 (plus poster) abstr. LB2-29, Dec. 2005. Summary in 2 parts (Part A). Canada [English]. Clinical Trials Insight
26. Okumu F, Walsh RB, Sears P, et al. Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: 204, 30 Oct. 2004. USA [English]
27. Gorbach S, Weiss K, Sears P, et al. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy: abstr. L1-1640, 12 Sep. 2009. Available from URL: http://www.icaac.org. USA [English]
28. Optimer Pharmaceuticals Inc. Optimer Presents Positive Data on Two Lead Anti-Infective Drug Candidates. www.optimerpharma.com, 21 Sep. 2007 Media Release
29. Credito KL, Appelbaum PC. Antianaerobic activity of OPT 80 compared to other agents. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: 204, 30 Oct. 2004. USA [English]
30. Goldstein E. Comparative Fidaxomicin Susceptibilities of Isolates Collected at Baseline, Failure, and Recurrence from Patients in a Phase III Trial of Clostridium difficile Infection (CDI). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy: abstr. L1-1641, 12 Sep. 2009. Available from URL: http://www.icaac.org. USA [English]
31. Louie TJ, Emery J, Krulicki W, Byrne B. PAR-101 is selectively effective against C. difficile in vivo, and has minimal effect on the anaerobic fecal flora. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy: Final Program: 227 (plus poster) abstr. LB2-30, Dec. 2005. Canada [English]
32. Miller MA, Mullane KM, Weiss K, et al. Age, serum albumin, and leukocytosis/fever predict clinical outcomes of Clostridium difficile infection treated with fidaxomicin and vancomycin. 47th Annual Meeting of the Infectious Diseases Society of America: abstr. 420, 29 Oct. 2009. Available from URL: http://www.idsociety.org/IDSA2009.htm. Canada [English]
33. Miller MA, Mullane KM, Weiss K, et al. Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection. 47th Annual Meeting of the Infectious Diseases Society of America: abstr. 422, 29 Oct. 2009. Available from URL: http://www.idsociety.org/IDSA2009. htm. Canada [English]
34. Mullane KM, Miller MA, Weiss K, et al. Effect of concomitant antibiotics on treatment of Clostridium difficile infection with fidaxomicin or vancomycin. 47th Annual Meeting of the Infectious Diseases Society of America: abstr. LB-14, 29 Oct. 2009. Available from URL: http://www.idsociety.org/IDSA2009.htm. USA [English]
35. Golan Y, Mullane K, Miller M, et al. Low Recurrence Rate among Patients (Pts) with C. difficile Infection (CDI) Treated with Fidaxomicin (FDX) 49th Interscience Conference on Antimicrobial Agents and Chemotherapy: abstr. L1-1639, 12 Sep. 2009. Available from URL: http://www.icaac.org. USA [English]. Clinical Trials Insight
36. Gerding D, Sambol S, Nagaro K, et al. Restriction endonuclease analysis typing of Clostridium difficile in a phase 3 treatment trial of fidaxomicin vs vancomycin: decreased cure rate for epidemic BI/NAP1/027 strain. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy: abstr. L1-1642, 12 Sep. 2009. Available from URL: http://www.icaac.org. USA [English]
37. Optimer Pharmaceuticals Inc. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin (R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI. www.optimerpharma.com, 02 Jun. 2009 Media Release